Cantex Pharmaceuticals, Inc. Receives FDA Fast Track Designation For CX-01 For The Treatment Of Patients Over Age 60 With Newly Diagnosed Acute Myeloid Leukemia (AML)

WESTON, Fla., Aug. 27, 2018 /PRNewswire/ — Cantex Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing proprietary pharmaceuticals for the treatment of cancer, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation for Cantex’s lead product candidate, CX-01, for the treatment of patients over age 60 receiving induction therapy for newly diagnosed acute myeloid […]

Read more

FDA Approves Oxervate

August 22, 2018 — The U.S. Food and Drug Administration today approved the first drug, Oxervate (cenegermin), for the treatment of neurotrophic keratitis, a rare disease affecting the cornea (the clear layer that covers the colored portion of the front of the eye). “While the prevalence of neurotrophic keratitis is low, the impact of this serious condition on an individual […]

Read more

How To Save on Insulin — With or Without Insurance Coverage

Steps for insured patients If you’re about to take insulin, choose one that’s preferred: If you’re already taking insulin, but NOT one that’s preferred, here’s what you can do: If you and your doctor don’t want to switch your insulin, this is where your endocrine or internist’s office can fill out a “prior authorization” stating that you have to be […]

Read more

Are You Waiting for a Chantix Generic? Here’s How To Save on the Popular Smoking Cessation Drug

What is Chantix? Chantix is a popular, but expensive, prescription drug used for smoking cessation. Research shows that the medication works, particularly if patients also enroll in counseling and support programs. Keep in mind that Chantix can have some serious side effects like nightmares, suicidal thoughts and amnesia. In fact, these side effects were so severe that Chantix once had […]

Read more

TG Therapeutics Announces Completion of Target Enrollment in the ULTIMATE Phase 3 Trials in Multiple Sclerosis

NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that target enrollment in the ULTIMATE I and II Phase 3 trials has been achieved. ULTIMATE I and II are two independent Phase 3 clinical trials evaluating the safety and efficacy of ublituximab (TG-1101), the Company’s glycoengineered anti-CD20 monoclonal antibody, as compared to teriflunomide, in […]

Read more

Cara Therapeutics Doses First Patient in Second Pivotal Phase 3 Efficacy Trial of Korsuva (CR845/difelikefalin) Injection in Hemodialysis Patients with Chronic Kidney Disease-Associated Pruritus

STAMFORD, Conn., Aug. 07, 2018 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced the dosing of the first patient in its second pivotal Phase 3 efficacy trial (KALM™-2) of Korsuva (CR845/difelikefalin) injection in hemodialysis patients […]

Read more

FDA Approves Kalydeco (ivacaftor) for Cystic Fibrosis in Children Ages 12 to <24 Months with Certain Mutations in the CFTR Gene

BOSTON–(BUSINESS WIRE)–Aug. 15, 2018– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved Kalydeco (ivacaftor) to include use in children with cystic fibrosis (CF) ages 12 to <24 months who have at least one mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to Kalydeco based on clinical and/or in […]

Read more

12 Brand-Name Drugs That May Never Go Generic

A recent analysis by I-MAK reveals that drug makers have leveraged the patent system to prevent generic competition, retain monopolies on expensive drugs and raise drug prices. This research comes months after the Trump administration released the American Patients First blueprint for lowering drug prices. Among the many initiatives included in the blueprint, the administration discussed strategies for increasing access […]

Read more

Study: What patients really think about opioid vs non-opioid medications for chronic pain

Prescriptions of opioids for chronic pain has increased dramatically since the 1990s in spite of their known harms. Despite a shortage of scientific studies on the long-term effectiveness of opioids such as morphine, oxycodone and hydrocodone, they are frequently perceived to be stronger, more powerful pain relievers than non-opioid alternatives like acetaminophen or ibuprofen. A new study investigates pre-existing perceptions […]

Read more
1 19 20 21 22 23